Ropes & Gray represented Pfizer Inc. in its agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million).
The transaction, announced June 22, is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to close in the second half of 2015.
The Ropes & Gray team was led by mergers & acquisitions partner Christopher Comeau.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.